Livforsakringsbolaget Skandia Omsesidigt Purchases 822 Shares of Danaher Co. (NYSE:DHR)

Livforsakringsbolaget Skandia Omsesidigt lifted its position in shares of Danaher Co. (NYSE:DHR) by 19.9% during the fourth quarter, Holdings Channel reports. The firm owned 4,954 shares of the conglomerate’s stock after acquiring an additional 822 shares during the period. Livforsakringsbolaget Skandia Omsesidigt’s holdings in Danaher were worth $1,147,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in DHR. Moneta Group Investment Advisors LLC increased its holdings in Danaher by 96,490.5% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 23,287,013 shares of the conglomerate’s stock worth $6,180,839,000 after buying an additional 23,262,904 shares during the last quarter. Norges Bank purchased a new position in shares of Danaher in the fourth quarter worth about $2,057,164,000. Wellington Management Group LLP increased its stake in shares of Danaher by 18.6% in the third quarter. Wellington Management Group LLP now owns 24,930,281 shares of the conglomerate’s stock worth $6,185,203,000 after purchasing an additional 3,905,449 shares in the last quarter. Allen Investment Management LLC increased its stake in shares of Danaher by 1,440.7% in the third quarter. Allen Investment Management LLC now owns 1,100,399 shares of the conglomerate’s stock worth $273,009,000 after purchasing an additional 1,028,976 shares in the last quarter. Finally, J.P. Morgan Private Wealth Advisors LLC purchased a new position in shares of Danaher in the third quarter worth about $178,850,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Wall Street Analyst Weigh In

DHR has been the subject of several recent research reports. Royal Bank of Canada lifted their target price on shares of Danaher from $254.00 to $282.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 31st. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a research note on Wednesday, January 31st. Barclays boosted their price target on shares of Danaher from $240.00 to $260.00 and gave the stock an “equal weight” rating in a research note on Wednesday, April 10th. Citigroup boosted their price target on shares of Danaher from $255.00 to $280.00 and gave the stock a “buy” rating in a research note on Wednesday, January 31st. Finally, KeyCorp upped their price objective on shares of Danaher from $260.00 to $290.00 and gave the company an “overweight” rating in a research note on Thursday, February 1st. Six equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $268.27.

Danaher Stock Down 1.7 %

Shares of NYSE DHR opened at $235.27 on Thursday. The company has a current ratio of 1.68, a quick ratio of 1.37 and a debt-to-equity ratio of 0.31. Danaher Co. has a 12 month low of $182.09 and a 12 month high of $259.00. The firm has a market capitalization of $174.23 billion, a PE ratio of 37.46, a price-to-earnings-growth ratio of 3.65 and a beta of 0.83. The firm has a fifty day simple moving average of $249.28 and a two-hundred day simple moving average of $229.86.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, January 30th. The conglomerate reported $2.09 EPS for the quarter, topping the consensus estimate of $1.91 by $0.18. Danaher had a net margin of 17.26% and a return on equity of 12.25%. The business had revenue of $6.41 billion during the quarter, compared to analyst estimates of $6.10 billion. During the same period in the prior year, the business earned $2.87 EPS. The company’s revenue for the quarter was down 10.2% on a year-over-year basis. Equities analysts expect that Danaher Co. will post 7.62 earnings per share for the current year.

Danaher Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 26th. Shareholders of record on Thursday, March 28th will be issued a $0.27 dividend. The ex-dividend date of this dividend is Wednesday, March 27th. This is a positive change from Danaher’s previous quarterly dividend of $0.24. This represents a $1.08 annualized dividend and a yield of 0.46%. Danaher’s dividend payout ratio is 16.90%.

Insider Buying and Selling

In related news, Director Teri List sold 3,289 shares of the stock in a transaction dated Tuesday, February 6th. The shares were sold at an average price of $248.32, for a total value of $816,724.48. Following the completion of the transaction, the director now directly owns 19,726 shares in the company, valued at approximately $4,898,360.32. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, Director Teri List sold 3,289 shares of the stock in a transaction dated Tuesday, February 6th. The shares were sold at an average price of $248.32, for a total value of $816,724.48. Following the completion of the transaction, the director now directly owns 19,726 shares in the company, valued at approximately $4,898,360.32. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Daniel Raskas sold 23,757 shares of the stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $252.00, for a total transaction of $5,986,764.00. Following the completion of the transaction, the senior vice president now owns 38,102 shares of the company’s stock, valued at $9,601,704. The disclosure for this sale can be found here. Insiders sold a total of 32,957 shares of company stock worth $8,265,802 in the last three months. 11.10% of the stock is owned by corporate insiders.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.